In trading on Thursday, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) entered into oversold territory, hitting an RSI reading of 24.8, after changing hands as low as $377.85 per share.

View Vertex Pharmaceuticals Incorporated (VRTX) current and estimated P/E ratio data provided by Seeking Alpha.

Shares of Vertex Pharmaceuticals fell more than 10% premarket Thursday, on track to hit lows last seen in early May, ...

In a recent transaction, Vertex Pharmaceuticals Inc.'s (NASDAQ:VRTX) Executive Vice President and Chief Medical Officer, Dr. Carmen Bozic, sold 2,280 shares of the company's common... ByInvesting ...

VRTX does not currently pay a dividend.

- Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY™ -- Safety profile consistent with ...

Brookdale Senior Living Inc. ("Brookdale" or the "Company") announced today that the Company has recently completed a successful advance refinancing of more than $300 million of the Company's 2027 ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...